STUDY OBJECTIVE: To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on β-cell function. DESIGN: A randomized, double-blind, placebo-controlled trial. SETTING:Seven hospitals in Italy. PATIENTS: A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%. INTERVENTION: After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months. MEASUREMENTS AND MAIN RESULTS:Body mass index, HbA(1c), fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index, homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPPr), proinsulin-to-fasting plasma insulin ratio (Pr:FPI ratio), C-peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. HbA(1c) was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-β C-peptide, and all measures of β-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group-to-group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. CONCLUSIONS: The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, β-cell function, and inflammatory parameters.
RCT Entities:
STUDY OBJECTIVE: To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on β-cell function. DESIGN: A randomized, double-blind, placebo-controlled trial. SETTING: Seven hospitals in Italy. PATIENTS: A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA(1c)) level higher than 7.5%. INTERVENTION: After an open-label run-in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months. MEASUREMENTS AND MAIN RESULTS: Body mass index, HbA(1c), fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index, homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPPr), proinsulin-to-fasting plasma insulin ratio (Pr:FPI ratio), C-peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. HbA(1c) was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-β C-peptide, and all measures of β-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group-to-group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. CONCLUSIONS: The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, β-cell function, and inflammatory parameters.
Authors: Robert A Scott; Daniel F Freitag; Li Li; Audrey Y Chu; Praveen Surendran; Robin Young; Niels Grarup; Alena Stancáková; Yuning Chen; Tibor V Varga; Hanieh Yaghootkar; Jian'an Luan; Jing Hua Zhao; Sara M Willems; Jennifer Wessel; Shuai Wang; Nisa Maruthur; Kyriaki Michailidou; Ailith Pirie; Sven J van der Lee; Christopher Gillson; Ali Amin Al Olama; Philippe Amouyel; Larraitz Arriola; Dominique Arveiler; Iciar Aviles-Olmos; Beverley Balkau; Aurelio Barricarte; Inês Barroso; Sara Benlloch Garcia; Joshua C Bis; Stefan Blankenberg; Michael Boehnke; Heiner Boeing; Eric Boerwinkle; Ingrid B Borecki; Jette Bork-Jensen; Sarah Bowden; Carlos Caldas; Muriel Caslake; L Adrienne Cupples; Carlos Cruchaga; Jacek Czajkowski; Marcel den Hoed; Janet A Dunn; Helena M Earl; Georg B Ehret; Ele Ferrannini; Jean Ferrieres; Thomas Foltynie; Ian Ford; Nita G Forouhi; Francesco Gianfagna; Carlos Gonzalez; Sara Grioni; Louise Hiller; Jan-Håkan Jansson; Marit E Jørgensen; J Wouter Jukema; Rudolf Kaaks; Frank Kee; Nicola D Kerrison; Timothy J Key; Jukka Kontto; Zsofia Kote-Jarai; Aldi T Kraja; Kari Kuulasmaa; Johanna Kuusisto; Allan Linneberg; Chunyu Liu; Gaëlle Marenne; Karen L Mohlke; Andrew P Morris; Kenneth Muir; Martina Müller-Nurasyid; Patricia B Munroe; Carmen Navarro; Sune F Nielsen; Peter M Nilsson; Børge G Nordestgaard; Chris J Packard; Domenico Palli; Salvatore Panico; Gina M Peloso; Markus Perola; Annette Peters; Christopher J Poole; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Veikko Salomaa; María-José Sánchez; Naveed Sattar; Stephen J Sharp; Rebecca Sims; Nadia Slimani; Jennifer A Smith; Deborah J Thompson; Stella Trompet; Rosario Tumino; Daphne L van der A; Yvonne T van der Schouw; Jarmo Virtamo; Mark Walker; Klaudia Walter; Jean E Abraham; Laufey T Amundadottir; Jennifer L Aponte; Adam S Butterworth; Josée Dupuis; Douglas F Easton; Rosalind A Eeles; Jeanette Erdmann; Paul W Franks; Timothy M Frayling; Torben Hansen; Joanna M M Howson; Torben Jørgensen; Jaspal Kooner; Markku Laakso; Claudia Langenberg; Mark I McCarthy; James S Pankow; Oluf Pedersen; Elio Riboli; Jerome I Rotter; Danish Saleheen; Nilesh J Samani; Heribert Schunkert; Peter Vollenweider; Stephen O'Rahilly; Panos Deloukas; John Danesh; Mark O Goodarzi; Sekar Kathiresan; James B Meigs; Margaret G Ehm; Nicholas J Wareham; Dawn M Waterworth Journal: Sci Transl Med Date: 2016-06-01 Impact factor: 17.956
Authors: Sushrima Gan; Adem Y Dawed; Louise A Donnelly; Anand T N Nair; Colin N A Palmer; Viswanathan Mohan; Ewan R Pearson Journal: Diabetes Care Date: 2020-08 Impact factor: 19.112
Authors: Jelena Vekic; Aleksandra Zeljkovic; Khalid Al Rasadi; Mustafa Cesur; José Silva-Nunes; Anca Pantea Stoian; Manfredi Rizzo Journal: Metabolites Date: 2022-01-24